{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T10:39:52Z","timestamp":1793270392614,"version":"4.5.0"},"reference-count":23,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Surg"],"DOI":"10.1001\/jamasurg.2020.4103","type":"journal-article","created":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T15:13:11Z","timestamp":1602083591000},"page":"e204103","source":"Crossref","is-referenced-by-count":94,"title":["Accuracy of Post\u2013Neoadjuvant Chemotherapy Image-Guided Breast Biopsy to Predict Residual Cancer"],"prefix":"10.1001","volume":"155","author":[{"given":"Marios Konstantinos","family":"Tasoulis","sequence":"first","affiliation":[{"name":"Department of Breast Surgery, The Royal Marsden NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Byoel","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Surgery, Seoul National University College of Medicine, Seoul, South Korea"},{"name":"Biomedical Research Institute, Seoul National University Hospital, Seoul, South Korea"},{"name":"Cancer Research Institute, Seoul National University, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Breast Imaging, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romney","family":"Pope","sequence":"additional","affiliation":[{"name":"Department of Radiology, The Royal Marsden NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savitri","family":"Krishnamurthy","sequence":"additional","affiliation":[{"name":"Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo-Yeon","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Radiology, Seoul National University Hospital, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nariya","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Radiology, Seoul National University Hospital, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Teoh","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, The Royal Marsden NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaiane M.","family":"Rauch","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin D.","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Valero","sequence":"additional","affiliation":[{"name":"Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kabir","family":"Mohammed","sequence":"additional","affiliation":[{"name":"Research and Development Department, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wonshik","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Surgery, Seoul National University College of Medicine, Seoul, South Korea"},{"name":"Biomedical Research Institute, Seoul National University Hospital, Seoul, South Korea"},{"name":"Cancer Research Institute, Seoul National University, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"MacNeill","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, The Royal Marsden NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry M.","family":"Kuerer","sequence":"additional","affiliation":[{"name":"Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2020,12,16]]},"reference":[{"issue":"6","key":"soi200066r1","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.jamcollsurg.2015.02.011","article-title":"Neoadjuvant chemotherapy for breast cancer increases the rate of breast conservation: results from the National Cancer Database.","volume":"220","author":"Killelea","year":"2015","journal-title":"J Am Coll Surg"},{"issue":"22","key":"soi200066r2","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","article-title":"Adjuvant capecitabine for breast cancer after preoperative chemotherapy.","volume":"376","author":"Masuda","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"soi200066r3","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer.","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"soi200066r4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1200\/JCO.2014.57.0572","article-title":"Impact of the addition of carboplatin and\/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).","volume":"33","author":"Sikov","year":"2015","journal-title":"J Clin Oncol"},{"issue":"9","key":"soi200066r5","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","article-title":"Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).","volume":"24","author":"Schneeweiss","year":"2013","journal-title":"Ann Oncol"},{"issue":"12","key":"soi200066r6","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S1470-2045(18)30570-9","article-title":"Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.","volume":"19","author":"van Ramshorst","year":"2018","journal-title":"Lancet Oncol"},{"issue":"14","key":"soi200066r7","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1001\/jama.2013.278932","article-title":"Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.","volume":"310","author":"Boughey","year":"2013","journal-title":"JAMA"},{"issue":"12","key":"soi200066r8","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1001\/jamasurg.2018.2696","article-title":"Association of low nodal positivity rate among patients with ERBB2-positive or triple-negative breast cancer and breast pathologic complete response to neoadjuvant chemotherapy.","volume":"153","author":"Barron","year":"2018","journal-title":"JAMA Surg"},{"issue":"10","key":"soi200066r9","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1200\/JCO.2015.64.0094","article-title":"Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection.","volume":"34","author":"Caudle","year":"2016","journal-title":"J Clin Oncol"},{"issue":"51","key":"soi200066r10","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/jncimonographs\/lgv003","article-title":"Radiotherapy issues after neoadjuvant chemotherapy.","volume":"2015","author":"Mak","year":"2015","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"1","key":"soi200066r11","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13058-016-0684-6","article-title":"Selective elimination of breast cancer surgery in exceptional responders: historical perspective and current trials.","volume":"18","author":"van la Parra","year":"2016","journal-title":"Breast Cancer Res"},{"key":"soi200066r12","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ejca.2016.09.034","article-title":"Can a pathological complete response of breast cancer after neoadjuvant chemotherapy be diagnosed by minimal invasive biopsy?","volume":"69","author":"Heil","year":"2016","journal-title":"Eur J Cancer"},{"issue":"11","key":"soi200066r13","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1038\/bjc.2015.381","article-title":"Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques.","volume":"113","author":"Heil","year":"2015","journal-title":"Br J Cancer"},{"issue":"5","key":"soi200066r14","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1097\/SLA.0000000000002313","article-title":"A clinical feasibility trial for identification of exceptional responders in whom breast cancer surgery can be eliminated following neoadjuvant systemic therapy.","volume":"267","author":"Kuerer","year":"2018","journal-title":"Ann Surg"},{"issue":"15_suppl","key":"soi200066r15","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1200\/JCO.2018.36.15_suppl.567","article-title":"Post neoadjuvant chemotherapy vacuum assisted biopsy in breast cancer: can it determine pathologic complete response before surgery?","volume":"36","author":"Tasoulis","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"soi200066r16","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s10549-020-05678-3","article-title":"Prediction of pathologic complete response using image-guided biopsy after neoadjuvant chemotherapy in breast cancer patients selected based on MRI findings: a prospective feasibility trial.","volume":"182","author":"Lee","year":"2020","journal-title":"Breast Cancer Res Treat"},{"issue":"suppl 1","key":"soi200066r17","article-title":"Image-guided vacuum-assisted biopsy to assess pathologic complete response in breast cancer patients with exceptional response to neoadjuvant chemotherapy.","volume":"5","author":"Teoh","year":"2019","journal-title":"J Global Oncol"},{"issue":"4","key":"soi200066r18","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.crad.2010.01.008","article-title":"Image-guided breast biopsy: state-of-the-art.","volume":"65","author":"O\u2019Flynn","year":"2010","journal-title":"Clin Radiol"},{"issue":"4 suppl","key":"soi200066r19","doi-asserted-by":"crossref","first-page":"GS5-03","DOI":"10.1158\/1538-7445.SABCS19-GS5-03","article-title":"Abstract GS5-03: diagnosing residual disease and pathologic complete response after neoadjuvant chemotherapy in breast cancer patients by image-guided vacuum-assisted breast biopsy: results of a prospective multicenter trial.","volume":"80","author":"Heil","year":"2020","journal-title":"Cancer Res"},{"issue":"4 suppl","key":"soi200066r20","doi-asserted-by":"crossref","first-page":"GS5-06","DOI":"10.1158\/1538-7445.SABCS19-GS5-06","article-title":"Abstract GS5-06: towards omitting breast surgery in patients with a pathologic complete response after neoadjuvant systemic treatment: interim analysis of the MICRA trial (Minimally Invasive Complete Response Assessment).","volume":"80","author":"Peeters","year":"2020","journal-title":"Cancer Res"},{"issue":"5","key":"soi200066r21","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/bjs.10807","article-title":"Meta-analysis of neoadjuvant therapy and its impact in facilitating breast conservation in operable breast cancer.","volume":"105","author":"Karakatsanis","year":"2018","journal-title":"Br J Surg"},{"issue":"suppl 5","key":"soi200066r22","article-title":"LBA8_PRKEYNOTE-522: phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC).","volume":"30","author":"Schmid","year":"2019","journal-title":"Ann Oncol"},{"issue":"7","key":"soi200066r23","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1001\/jamasurg.2017.0562","article-title":"Identification of patients with documented pathologic complete response in the breast after neoadjuvant chemotherapy for omission of axillary surgery.","volume":"152","author":"Tadros","year":"2017","journal-title":"JAMA Surg"}],"container-title":["JAMA Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamasurgery\/articlepdf\/2771053\/jamasurgery_tasoulis_2020_oi_200066_1608067497.5846.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T12:19:45Z","timestamp":1669119585000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamasurgery\/fullarticle\/2771053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,16]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamasurg.2020.4103","relation":{},"ISSN":["2168-6254"],"issn-type":[{"value":"2168-6254","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12,16]]}}}